Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

NARecruitingINTERVENTIONAL
Enrollment

785

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
PertussisDiphtheriaTetanusHaemophilus Influenzae Type B InfectionPolio
Interventions
PROCEDURE

Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine

"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."

Trial Locations (1)

210009

RECRUITING

Jingsu Provincial Centre of Disease Control and Prevention, Nanjing

All Listed Sponsors
lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK